Chronic kidney disease (CKD) has become a worldwide public health issue with increasing prevalence in the United States. As kidney function declines, anemia or other complications may arise, and hemodialysis (HD) or kidney transplantation may be needed. Early intervention and treatment of CKD complications will improve clinical outcomes and may delay or prevent disease sequelae. Primary or adjuvant iron replacement in CKD patients with anemia is recommended. The National Kidney Foundation guidelines state that patients receiving erythropoiesis-stimulating agent (ESA) therapy and HD will require intravenous (IV) iron for optimal iron stores and ESA efficacy. This article, the first of a two-part series, details the optimization of IV iron therapy in CKD patients, clinical trial evaluation of IV versus oral iron in the non–HD-dependent CKD patient, and a comparison of the four available IV iron agents. The percent changes in ESA utilization in conjunction with iron therapy and the associated cost savings are also addressed. The second article in this series goes on to describe elements of the medication use process for care of CKD patients with anemia.
KDOQI, National Kidney Foundation.KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease [published correction appears in Am J Kidney Disease. 2006; 48(3):518]. Am J Kidney Dis.2006; 47(5) (suppl 3): S1–S145.
2.
SnivelyC.S., GutierrezC.Chronic kidney disease: prevention and treatment of common complications. Am Fam Physician.2004; 70(10): 1921–1928.
3.
AstorB.C., MuntnerP., LevinA., EustaceJ.A., CoreshJ.Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med.2002; 162(12): 1401–1408.
4.
KazmiW.H., KauszA.T., KhanS.. Anemia: an early complication of chronic renal insufficiency. Am J Kidney Dis.2001; 38(4): 803–812.
5.
LocatelliF., AljamaP., BaranyP.. European Best Practice Guidelines Working Group. Revised European Best Practice Guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant.2004; 19(suppl 2): ii1–ii47.
6.
AstorB.C., CoreshJ.C., HeissG., PettittD., SarnakM.J.Kidney function and anemia as risk factors for coronary heart disease and mortality: the Atherosclerosis Risk in Communities (ARIC) study. Am Heart J.2006; 151(2): 492–500.
7.
CollinsA.J.The hemoglobin link to adverse outcomes. Adv Stud Med.2003; 3(3C): S194–S197.
8.
McClellanW.M., FlandersW.D., LangstonR.D., JurkovitzC., PresleyR.Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: a population-based study. J Am Soc Nephrol.2002; 13(7): 1928–1936.
9.
Al-AhmadA., RandW.M., ManjunathG.. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol.2001; 38(4): 955–962.
10.
FinkJ.C., BlahutS.A., ReddyM., WeirM.R.Use of erythropoietin before the initiation of dialysis and its impact on mortality. Am J Kidney Dis.2001; 37(2): 348–355.
11.
GouvaC., NikolopoulosP., IoannidisJ.P., SiamopoulosK.C.Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int.2004; 66(2): 753–760.
12.
AmerlingR., EasonA., JuergensenP.Updating practices in an evolving IV iron and anemia environment: practical solutions. Nephrol Nurs J.2007; 34(5): 533–541.
13.
StevensP.Optimizing renal anaemia management—benefits of early referral and treatment. Nephrol Dial Transplant.2005; 20(suppl 8): viii22–viii26.
14.
PhillipsM.S., GaymanJ.E., ToddMW; American Society of Health-System Pharmacists. ASHP guidelines on medication-use evaluation. Am J Health Syst Pharm.1996; 53(16): 1953–1955.
15.
FishbaneS.Iron management in nondialysis-dependent CKD. Am J Kidney Dis.2007; 49(6): 736–743.
16.
St PeterW.L., ObradorG.T., RobertsT.L., CollinsA.J.Trends in intravenous iron use among dialysis patients in the United States (1994-2002). Am J Kidney Dis.2005; 46(4): 650–660.
17.
DowlingT.C.Prevalence, etiology, and consequences of anemia and clinical economic benefits of anemia correction in patients with chronic kidney disease: an overview. Am J Health Syst Pharm.2007; 64(suppl 8): S3–S7.
18.
ObradorG.T., RobertsT., St PeterW.L., FrazierE., PereiraB.J., CollinsA.J.Trends in anemia at initiation of dialysis in the United States. Kidney Int.2001; 60: 1875–1884.
19.
TarngD.Cardiorenal anemia syndrome in chronic kidney disease. J Chin Med Assoc.2007; 70(10): 424–429.
20.
Morbidity and mortality of dialysis.NIH Consens Statement.1993; 11(2): 1–33.
21.
KDOQI.KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease: 2007 update of hemoglobin target. Am J Kidney Dis.2007; 50(3): 471–530.
22.
MircescuG., GârneaţăL., CăpuşăC., UrseaN.Intravenous iron supplementation for the treatment of anaemia in pre-dialyzed chronic renal failure patients. Nephrol Dial Transplant.2006; 21(1): 120–124.
23.
Van WyckD.B.Lessons from NKF-DOQI: iron management. Semin Nephrol.2000; 20(4): 330–334.
24.
GotloibL., SilverbergD., FudinR., ShostakA.Iron deficiency is a common cause of anemia in chronic kidney disease and can often be corrected with intravenous iron. J Neprol.2006; 19(2): 161–167.
25.
HallbergL., RyttingerL., SolvellL.Side-effects of oral iron therapy: a double-blind study of different iron compounds in tablet form. Acta Med Scand.1966; 181: S3–S10.
26.
CharytanC., QunibiW., BailieG.R.Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysis. Nephron Clin Pract.2005; 100(3): c55–c62.
27.
Van Wyck DB, Roppolo M, Martinez CO, Mazey RM, McMurray S; for the United States Iron Sucrose (Venofer) Clinical Trials Group.A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. Kidney Int.2005; 68(6): 2846–2856.
28.
StovesJ., InglisH., NewsteadC.G.A randomized study of oral vs intravenous iron supplementation in patients with progressive renal insufficiency treated with erythropoietin. Nephrol Dial Transplant.2001; 16(5): 967–974.
29.
AggarwalH.K., NandN., SinghS., SinghM., Hemant, KaushikG.Comparison of oral versus intravenous iron therapy in predialysis patients of chronic renal failure receiving recombinant human erythropoietin. J Assoc Physicians India.2003; 51: 170–174.
30.
SpinowitzB.S., KauszA.T., BaptistaJ.. Ferumoxytol for treating iron deficiency anemia in CKD. J Am Soc Nephrol.2008; 19(8): 1599–1605.
31.
AgarwalR., RizkalaA., BastaniB., KaskasM., LeeheyD., BesarabA.A randomized controlled trial of oral versus intravenous iron in chronic kidney disease. Am J Nephrol.2006; 26(5): 445–454.
32.
SilverbergD.S., BlumM., AgbariaZ.. The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period. Clin Nephrol.2001; 55(3): 212–219.
33.
SilverbergD., IainaA., PeerG.. Intravenous iron supplementation for the treatment of anemia of moderate to severe chronic renal failure patients not receiving dialysis. Am J Kidney Dis.1996; 27(2): 234–238.
34.
SchaeferR.M., SchaeferL.Management of iron substitution during r-HuEPO therapy in chronic renal failure patients. Erythropoiesis.1992; 3: 71–75.
35.
NyvadO., DanielsonH., MadsenS.Intravenous iron-sucrose complex to reduce epoetin demand in dialysis patients. Lancet.1994; 344(8932): 1305–1306.
36.
FishbaneS., FreiG.L., MaesakaJ.Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron administration. Am J Kidney Dis.1995; 26(1): 41–46.
37.
Sunder-PlassmanG., HorlW.H.Optimizing low dose r-HuEPO combined with low dose I.V. iron therapy in hemodialysis patients. J Am Soc Nephrol.1994; 5: 478.
38.
AhsanN., GroffJ.A., WaybillM.A.Efficacy of bolus intravenous iron dextran treatment in peritoneal dialysis patients receiving recombinant human erythropoietin. Adv Perit Dial.1996; 12: 161–166.
39.
SilverbergD.S., BlumM., AgbariaZ., PeerG., KaplanE., IainaA.Intravenous ferric saccharate as an iron supplement in dialysis patients. Nephron.1996; 72(3): 413–417.
40.
SepandjF., JindallK., WestM., HirschD.Economic appraisal of maintenance parenteral iron administration in the treatment of anaemia in chronic hemodialysis patients. Nephrol Dial Transplant.1996; 11(2): 319–322.
41.
TaylorJ.E., PeatN., PorterC., MorganA.G.Regular low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients. Nephrol Dial Transplant.1996; 1(6): 1079–1083.
42.
MacdougallI.C., TuckerB., ThompsonJ.. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int.1996; 50(5): 1694–1699.
43.
KimuraT., AraiM., MasudaH., KawabataA.Impact of a pharmacist-implemented anemia management in outpatients with end-stage renal disease in Japan. Biol Pharm Bull.2004; 27(11): 1831–1833.
44.
EschbachJ.W.Iron requirements in erythropoietin therapy. Best Pract Res Clin Haematol.2005; 18(2): 347–361.
Venofer [package insert].Shirley, NY: American Regent, Inc.; 2007.
49.
KudashevaD.S., LaiJ., UlmanA., CowmanM.K.Structure of carbohydrate-bound polynuclear iron oxyhydroxide nanoparticles in parenteral formulations. J Inorg Biochem.2004; 98(11): 1757–1769.
50.
SasakC.Supporting epoetin alfa stimulated erythropoiesis: identifying appropriate iron levels: case study of the anemic patient. Nephrol Nurs J.2000; 27(6): 612–614.
51.
CharytanC., SchwenkM.H., Al-SaloumM.M., SpinowitzB.S.Safety of iron sucrose in hemodialysis patients intolerant to other parenteral iron products. Nephron Clin Pract.2004; 96(2): c63–c66.
52.
IMS Health.IMS National Health Perspectives (1999-2009).
53.
DanielsonB.G.Structure, chemistry, and pharmacokinetics of intravenous iron agents. J Am Soc Nephrol.2004; 15(suppl 2): S93–S98.
54.
MichaelB., CoyneD.W., FishbaneS..; Ferrlecit Publication Committee. Sodium ferric gluconate complex in hemodialysis patients: Adverse reactions compared to placebo and iron dextran. Kidney Int.2002; 61(5): 1830–1839.
55.
FishbaneS., UngureanuV.D., MaesakaJ.K., KaupkeC.J., LimV., WishJ.The safety of intravenous iron dextran in hemodialysis patients. Am J Kidney Dis.1996; 28(4): 529–534.
56.
ProvenzanoR., SchillerB., RaoM., CoyneD., BrennerL., PereiraB.J.Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients. Clin J Am Soc Nephrol.2009; 4(2): 386–393.
57.
BalakrishnanV.S., RaoM., KauszA.T.. Physiochemical properties of ferumoxytol, a new intravenous iron preparation. Eur J Clin Invest.2009; 39(6): 489–496.
AronoffG.R., BennettW.M., BlumenthalS..; United States Iron Sucrose (Venofer) Clinical Trials Group. Iron sucrose in hemodialysis patients: safety and efficacy of iron replacement and maintenance therapy. Kidney Int.2004; 66(3): 1193–1198.
